Through PT Dexa Medica and PT Ferron Par Pharmaceuticals, Dexa Group has been awarded the Indonesia Best Companies in Adopting Local Content Award 2024 by SWA Magazine. This prestigious recognition highlights the company’s success in optimizing local resources, including raw materials, technology, and workforce.
The award was presented by Mr. Kemal Effendi Gani, Chairman of SWA Media Group, to Mr. Benny Sutisna Suwarno, President Director of PT Ferron Par Pharmaceuticals, and Mr. Budi Herlambang, Finance Director of PT Dexa Medica, in Jakarta on Tuesday, December 17, 2024.
Mr. Kemal explained that the Indonesia Best Companies in Adopting Local Content Award is a selection program recognizing best practices by companies excelling in adopting local content, fostering collaboration to promote economic growth and domestic industry development through a rigorous jury assessment process.
“I would like to quote Professor Ha-Joon Chang from his book Bad Samaritans: The Myth of Free Trade and the Secret History of Capitalism, which states that using and developing local components is not merely about import substitution. It is about empowering domestic industries to move up the global value chain and achieve long-term growth,” Mr. Kemal elaborated.
After receiving the award, Mr. Benny and Mr. Budi expressed their gratitude to all Dexan. “Today, Dexa and Ferron have received an award from SWA Magazine for implementing local content. This prestigious award affirms our commitment to supporting local content in Indonesia. For instance, PT Ferron has been active in producing the raw material Omeprazole and remains committed to manufacturing oncology medicines through PT Fonko. These efforts have garnered significant appreciation through Indonesia’s Best Companies in Adopting Local Content Award 2024. This award is an honor for Dexa Group and reflects our contribution to Indonesia. Let’s keep up the spirit. Thank you,” said Mr. Benny.
Mr. Budi Herlambang shared a similar sentiment. “Congratulations to Dexa and Ferron for receiving the Indonesia Best Companies in Adopting Local Content Award 2024 from SWA. PT Dexa has strongly supported the government’s programs for independence in pharmaceutical raw materials through Obat Modern Asli Indonesia (OMAI) and generic drugs (OGB) for the National Health Insurance (JKN) program. We hope Dexa will continue contributing and encourage the use of products from Dexa Medica and Ferron Par Pharmaceuticals.”
The Indonesia Best Companies in Adopting Local Content Award 2024 was awarded to PT Dexa Medica and PT Ferron Par Pharmaceuticals after a rigorous assessment process by a distinguished panel of judges on November 13, 2024. The jury included Mr. Warih Andang Tjahjono (Former President Director of Toyota Motor Manufacturing Indonesia), Mr. Rudiyanto (Former CEO of Biro Klasifikasi Indonesia), and Mr. Gendut Suprayitno (Chairman of The Indonesian Institute for Corporate Governance – IICG). The companies earned the “Very Good” designation, the highest rating in the awards program.
Contributions by PT Dexa Medica and PT Ferron Par Pharmaceuticals
In line with the award, PT Dexa Medica has developed pharmaceutical products with a high Local Content Level (Tingkat Komponen Dalam Negeri or TKDN), including OMAI products such as Stimuno (90% TKDN), HerbaASIMOR (81.09%), Diabetadex (81.83%), Redacid (83.64%), Disolf (81.25%), and Inlacin (82.30%). Additionally, Dexa Medica produces high-quality OGB drugs with significant TKDN values, such as Omeprazole (52.80%), Clopidogrel (68.33%), and Atorvastatin (67.75%), which are integral to the JKN program.
Meanwhile, PT Ferron Par Pharmaceuticals has played a pivotal role in marketing oncology products, with TKDN exceeding 25%, manufactured by PT Fonko International Pharmaceuticals. Ferron leads the initiative in producing and distributing locally made cancer drugs. Currently, 29 SKUs of Fonko’s oncology products are listed in the national e-catalog and utilized by BPJS patients.
Notable oncology drugs manufactured by PT Fonko include Fonkozomib (Bortezomib) for multiple myeloma therapy (35.01% TKDN), Bendamustine for Chronic Lymphocytic Leukemia and Non-Hodgkin’s Lymphoma (35.01%), Fontrexed for lung cancer treatment (33.56%), and Cyclophosphamide for carcinoma and sarcoma therapy (37.93%).
Dexa Group continues to promote the TKDN initiative across the pharmaceutical production value chain—from raw materials, research, and manufacturing processes to packaging. This effort enhances the competitiveness of domestic products and contributes to achieving pharmaceutical independence in Indonesia.